Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.9M Buy
461,100
+456,500
+9,924% +$12.2M 0.02% 697
2025
Q4
$115K Sell
4,600
-106,300
-96% -$2.68M ﹤0.01% 2185
2025
Q3
$2.83M Sell
110,900
-456,600
-80% -$11.3M ﹤0.01% 1285
2025
Q2
$13.8M Buy
567,500
+197,100
+53% +$4.6M 0.03% 650
2025
Q1
$9.39M Buy
370,400
+336,100
+980% +$8.79M 0.02% 755
2024
Q4
$910K Sell
34,300
-101,200
-75% -$2.75M ﹤0.01% 1512
2024
Q3
$3.92M Buy
135,500
+1,200
+0.9% +$35K 0.01% 1110
2024
Q2
$3.76M Buy
134,300
+32,200
+32% +$887K 0.01% 1130
2024
Q1
$2.83M Sell
102,100
-12,100
-11% -$336K 0.01% 1175
2023
Q4
$3.29M Buy
+114,200
New +$3.45M 0.01% 1119

Other funds holding PFE

Man Group's PFE Position: Q1 2026 in Review

Man Group reduced its Pfizer (PFE) stake by 61% in Q1 2026, selling an estimated $41M and leaving 986,121 shares worth $27.7M. The position accounts for 0.05% of the portfolio, ranked #382.

Man Group first reported a position in PFE in Q1 2018 and has held it in 30 quarters since. The position peaked at $117M in Q1 2022. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Man Group held 986,121 shares of Pfizer worth $27.7M as of Q1 2026.
  • Man Group sold 1,539,479 Pfizer shares in Q1 2026, an estimated $41M.
  • Pfizer made up 0.05% of Man Group's portfolio in Q1 2026, its #382 holding.
  • Man Group first reported a position in Pfizer in Q1 2018 and has held it in 30 quarters since.
  • Man Group's Pfizer position peaked at $117M in Q1 2022.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.